BML Capital Management LLC Purchases 480,267 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

BML Capital Management LLC increased its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 61.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,261,559 shares of the biotechnology company’s stock after acquiring an additional 480,267 shares during the quarter. Oramed Pharmaceuticals comprises about 2.2% of BML Capital Management LLC’s holdings, making the stock its 11th biggest holding. BML Capital Management LLC’s holdings in Oramed Pharmaceuticals were worth $2,914,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. N.E.W. Advisory Services LLC bought a new position in shares of Oramed Pharmaceuticals in the third quarter valued at approximately $34,000. Algert Global LLC purchased a new stake in Oramed Pharmaceuticals in the third quarter valued at approximately $38,000. Barclays PLC raised its stake in Oramed Pharmaceuticals by 39.0% in the third quarter. Barclays PLC now owns 18,406 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 5,167 shares in the last quarter. Finally, Rathbones Group PLC purchased a new stake in Oramed Pharmaceuticals in the third quarter valued at approximately $756,000. 12.73% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Price Performance

Shares of ORMP opened at $2.35 on Wednesday. The firm’s 50 day simple moving average is $2.88 and its 200 day simple moving average is $2.48. The company has a market capitalization of $95.22 million, a P/E ratio of 16.79 and a beta of 1.81. Oramed Pharmaceuticals Inc. has a 1-year low of $1.67 and a 1-year high of $5.25.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04. On average, equities analysts anticipate that Oramed Pharmaceuticals Inc. will post -0.26 earnings per share for the current year.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.